News
News from us and our partners
Tags
Topics
0 results
- News
Muna Therapeutics Announces Positive Phase 1 Results Supporting Potential of Oral Small-Molecule TREM2 Modulator, MNA-001, in Alzheimer’s Disease
- News
TISSIUM® Receives CE Mark for ECLIPSIUM®, Its Atraumatic Hernia Repair Solution
- News
F2G and Shionogi Report Data from Global Phase 3 OASIS Study Evaluating Investigational Oral Olorofim Versus AmBisome® Followed by Standard of Care in Invasive Aspergillosis in Late-Breaking Oral Presentation at IDWeek 2026
- News
Bionyra Pharma Announces Positive Interim Phase 1 Results for BYN-002, a Long-Acting Anti-TL1A Antibody
- News
IMIO Raises $12M from Sofinnova Partners and Chipotle's Cultivate Next to Scale Reliable Biologicals and Improve Soil Performance
- News
New Research from One Biosciences Shows Single-Cell Profiling Can Identify Which Ovarian Cancer Tumors are Predisposed to Chemotherapy Resistance
- News
Sensorion Announces the Appointment of Peter Weber, MD, MBA, as Chief Medical Officer
- News
TIME Names Recor Medical’s Paradise Ultrasound Renal Denervation System one of the Best Inventions of 2026
- News
COAPTIUM® CONNECT Named One of TIME’s Best Inventions of 2026
- News
Mission Therapeutics doses first Parkinson’s patient in Phase 1b study of potential disease-modifying treatment MTX325
- News
Sitryx Reports Positive Phase 1b Results for First-in-Class Oral PKM2 Modulator SYX-5219 in Patients with Moderate to Severe Atopic Dermatitis
- News
GenSight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa
- News
Sensorion Announces the Appointment of Louis J. Arcudi III as Chief Financial Officer
- News
GenSight Biologics Reports Cash Position as of September 30, 2026
- News
Mediar Therapeutics Completes Enrollment in Phase 2 WISPer Trial of MTX-463 in Idiopathic Pulmonary Fibrosis (IPF)